Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SLGL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $180.63M
- EPS (TTM)
- -$5.22
- Dividend yield
- None
- 52-week range
- 34.47 – 97.97
- Day range
- 51.81 – 56.16
- Volume / Avg
- 24.36K / 47.38K
- Beta
- —
- Shares outstanding
- 3.27M
52-week range
SLGL stock today
Shares of Sol-Gel Technologies (SLGL) finished higher on Nov 20 at $55.17, a gain of 2.02% or $1.09 per share, versus the S&P 500's 3.70% decline. At this level, SLGL sits in the middle of its 52-week range of $34.47 to $97.97: 43.7% below the high, set on Mar 3, 2026 and 60.1% above the low. SLGL is up 30.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 50.5%.
Sol-Gel Technologies has posted a net loss over the last twelve months (EPS of -$5.22), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Sol-Gel Technologies
Company profileSol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Moshe Arkin
- Headquarters
- Ness Ziona
- Employees
- 28
- IPO year
- 2018
- Website
- sol-gel.com
Financial highlights
Full financialsIn fiscal 2025, Sol-Gel Technologies generated $19.4 million in revenue, up 68.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Sol-Gel Technologies reported a net loss of $6.1 million, compared with a loss of $10.6 million a year earlier. Operating margin was -38.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $19.39M | $11.54M | $1.55M | $3.88M | $31.27M |
| Growth | +68.04% | +642.47% | -59.98% | -87.58% | +256.54% |
| Net income | $-6.13M | $-10.58M | $-27.24M | $-14.92M | $3.22M |
| EPS (diluted) | $-2.19 | $-3.79 | $-10.01 | $-0.65 | $0.14 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$155.50+181.86%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.72 vs $-1.54
- Surprise
- -11.69%
SLGL news
All SLGL news- Sol-Gel Technologies Ltd. Shareholders Approve CEO Appointment and Potential Name ChangeNasdaq
- Sol-Gel Technologies Ltd. Reports Third Quarter 2026 Financial Results and SGT-610 Clinical ProgressNasdaq
- Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Cantor Fitzgerald Initiates Coverage of Sol-Gel Technologies at OverweightNasdaq
Sol-Gel Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| WHWKWhitehawk Therapeutics Inc. | 3.07 | -1.60% | $181.16M | vs SLGL |
| ADCTADC Therapeutics SA | 1.28 | -1.54% | $180.05M | vs SLGL |
| NATRNature's Sunshine Products Inc. | 10.18 | +0.10% | $176.41M | vs SLGL |
| VOGXVogenx Inc | 11.87 | -7.30% | $176.33M | vs SLGL |
| RNACCartesian Therapeutics Inc. | 6.14 | +4.24% | $187.29M | vs SLGL |
| SIGASIGA Technologies Inc. | 2.40 | -9.43% | $172.45M | vs SLGL |
| TRDAEntrada Therapeutics Inc. | 4.35 | -6.25% | $170.30M | vs SLGL |
| ANTXAN2 Therapeutics Inc. | 5.08 | -2.68% | $192.75M | vs SLGL |
Indexes, lists and sector
Sol-Gel Technologies stock FAQ
What is Sol-Gel Technologies's stock price today?
SLGL last traded at $55.17 as of Nov 20, 4:00 PM EST, up 2.02% on the day. Prices are delayed at least 15 minutes.
Does Sol-Gel Technologies pay a dividend?
No. Sol-Gel Technologies does not currently pay a regular cash dividend.
Who is Sol-Gel Technologies's CEO?
Mr. Moshe Arkin is the chief executive officer of Sol-Gel Technologies Ltd., which has about 28 employees.
Has SLGL ever split its stock?
Yes. The most recent SLGL stock split was a 1-for-10 split on May 5, 2025.
What is the SLGL 52-week high?
The 52-week high for SLGL is $97.97 and the 52-week low is $34.47. The stock is currently 43.7% below its high.